Cost comparison analysis of onasemnogene abeparvovec and nusinersen for treatment of patients with spinal muscular atrophy type 1 in the Netherlands
Onasemnogene abeparvovec was less costly than nusinersen after 8.25 years of treatment of patients with SMA type 1 in the Netherlands.
Authors
- Cornelis Boersma (ORCID: https://orcid.org/0000-0002-1190-2638)
- Maarten Jacobus Postma (ORCID: https://orcid.org/0000-0002-6306-3653)
- M Bischof
- Ruth Howells
- Rimma Velikanova
- Simon van der Schans (ORCID: https://orcid.org/0000-0003-4602-6487)
- Diana Weidlich
- Anish Patel
Institutions
- Novartis (Switzerland) (CH)
- University Medical Center Groningen (NL)
- NorthShore University HealthSystem (US)
- University of Groningen (NL)
- Novartis (United States) (US)
- Novartis Gene Therapies Switzerland GmbH
- Open University of the Netherlands (NL)
Publication Details
- Journal
- The European Journal of Health Economics
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1007/s10198-024-01754-3
- Citations
- 2
- Primary Topic
- Neurogenetic and Muscular Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 3.25
Funders
- AveXis